Clinical Trial Update: MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial comparing MLN0128 (and MLN0128 + MLN1117) vs everolimus in adults with advanced or metastatic clear-cell renal cell carcinoma; study completed wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Everolimus (everolimus)
• MLN0128 (sapanisertib)
• MLN0128 + MLN1117

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Clear-cell Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-02-21